Bis-amide Compounds Inhibiting SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatments against SARS-CoV-2, as current therapies are inadequate for addressing the severe acute respiratory syndrome caused by this virus, particularly given its rapid evolution and high mortality rates.
Innovation Solution
Development of novel bis-amide compounds that inhibit SARS-CoV-2, specifically described by their chemical formulae and structures, which can be administered as pharmaceutical compositions to treat severe acute respiratory syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used against SARS-CoV-2, then treatment availability is maintained, but treatment effectiveness is inadequate due to the virus's rapid evolution and high mortality rates
Solution Approach 1:
The patent employs parameter changes by developing a series of bis-amide compounds with systematically varied molecular structures (different R groups, linkers, and substitutions) to optimize antiviral activity. This approach allows tuning of compound properties to effectively counter evolving viral strains while maintaining reliable treatment outcomes.
2Reliability
If novel bis-amide compounds are developed to inhibit SARS-CoV-2, then treatment effectiveness is improved, but development complexity and time are increased
Solution Approach 1:
The bis-amide compounds are designed with segmented modular structures consisting of distinct functional domains (R1, R2, R3, R4 groups and linkers). This segmentation allows independent optimization of each module for antiviral activity while simplifying the overall development process through systematic combination of proven structural elements.
Solution Approach 2:
The core bis-amide structure serves multiple functions: it provides the fundamental antiviral mechanism while allowing diverse substituent groups to target different viral proteins or entry pathways. This multi-functionality enables a single compound class to address multiple aspects of SARS-CoV-2 pathogenesis and adapt to viral evolution.
3Reliability
If novel bis-amide compounds are developed to inhibit SARS-CoV-2, then treatment effectiveness is improved, but development time and resource investment are increased
Solution Approach 1:
The patent performs preliminary action by conducting extensive in silico screenings and in vitro validations of bis-amide compounds before clinical development. This advance preparation of compound libraries and preliminary efficacy data reduces the time required for later development stages while ensuring therapeutic effectiveness is established early in the process.
Data Source
AI summary
Bis-amide inhibitors of SARS-CoV-2 (COVID), compositions, and methods of treating a severe acute respiratory syndrome.